teriflunomide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 14 Diseases   33 Trials   33 Trials   2608 News 


«12...4567891011121314...3132»
  • ||||||||||  Utuxin (ublituximab) / TG Therap
    Journal:  Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (Pubmed Central) -  Aug 31, 2022   
    P3
    Ublituximab was associated with infusion-related reactions. (Funded by TG Therapeutics; ULTIMATE I and II ClinicalTrials.gov numbers, NCT03277261 and NCT03277248.).
  • ||||||||||  Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Journal, IO biomarker:  How to choose initial treatment in multiple sclerosis patients: a case-based approach. (Pubmed Central) -  Aug 22, 2022   
    Strong evidence supports the use of early high efficacy therapy. However, biomarkers, clinical and radiologic prognostic factors, as well as patients' individual issues, should be valued and considered for a personalized treatment decision.
  • ||||||||||  fingolimod / Generic mfg.
    Journal:  SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. (Pubmed Central) -  Aug 18, 2022   
    The lack of immunogenicity under long-term fingolimod treatment demonstrates that functional immune responses require not only immune cells themselves, but also access of these cells to the site of inoculation and their unimpeded movement. The absence of humoral and T cell responses suggests that fingolimod-treated patients with MS are at risk for severe SARS-CoV-2 infections despite booster vaccinations, which is highly relevant for clinical decision-making and adapted protective measures, particularly considering additional recently approved sphingosine-1-phosphate receptor antagonists for MS treatment.
  • ||||||||||  teriflunomide / Generic mfg.
    SUBACUTE ASPIRATION PNEUMONIA IN AN IMMUNOCOMPROMISED PATIENT WITH MULTIPLE SCLEROSIS (Convention Center Exhibit Hall: Poster Area) -  Aug 16, 2022 - Abstract #CHEST2022CHEST_1958;    
    While SAP is common in patients with certain risk factors, it is a challenging diagnosis. Negative cultures should not rule out the diagnosis, particularly in patients with a suggestive clinical picture and autoimmune disease with recurrent pneumonias.
  • ||||||||||  teriflunomide / Generic mfg.
    Trial completion date, Trial primary completion date:  Mechanistic Studies of Teriflunomide in RRMS (clinicaltrials.gov) -  Jul 29, 2022   
    P=N/A,  N=30, Active, not recruiting, 
    This indicates the need for more active use of cladribine in tablets with active forms of MS. Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Journal:  Prediction of relapse activity when switching to cladribine for multiple sclerosis. (Pubmed Central) -  Jul 28, 2022   
    Data of patients who switched to cladribine, grouped by prior disease-modifying therapy (pDMT; interferon-β/glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod or natalizumab (NTZ)), were extracted from the MSBase Registry...Relapse during or prior to the treatment gap, and younger age, are of prognostic relevance in the year after switching to cladribine. Switching from NTZ is also independently associated with greater relapse hazard.
  • ||||||||||  Prediction of response in relapsing-remitting MS patients initiating oral DMTs (G104) -  Jul 23, 2022 - Abstract #ECTRIMS2022ECTRIMS_538;    
    Clinical-radiological measures integrated into the RS during the first year of treatment have an acceptable prognostic value for identifying clinical activity. However, RA may not be entirely comprised by LR scores, resulting in EDA for this group during follow-up.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    High efficacy disease modifying therapies increase the risk of cervical abnormalities in women with Multiple Sclerosis (G106) -  Jul 23, 2022 - Abstract #ECTRIMS2022ECTRIMS_506;    
    The risk of cervical abnormalities was more than three-fold higher in women exposed to high efficacy DMTs than low efficacy DMTs. This finding is vitally important for the safety of women with MS and will have direct clinical implications for primary and secondary prevention strategies including cervical cancer screening frequency and human papillomavirus (HPV) vaccination.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Trial completion date, Trial primary completion date:  TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) -  Jul 19, 2022   
    P=N/A,  N=900, Recruiting, 
    The study was funded by Janssen Research & Development, LLC. Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
  • ||||||||||  Utuxin (ublituximab) / TG Therap
    Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis: Pooled Post Hoc Analyses of ULTIMATE I and II (B3) -  Jul 18, 2022 - Abstract #EAN2022EAN_2514;    
    Evaluations of EDSS score improvements during treatment showed a consistent and significant benefit for ublituximab versus teriflunomide. Along with prespecified 12- and 24-week CDI analyses, pooled post hoc evaluations of sustained 12-week CDI and EDSS score provide further evidence of clinically meaningful disability improvement with ublituximab in ULTIMATE I and II.
  • ||||||||||  Ponvory (ponesimod) / J&J
    Ponesimod Effects on Relapse Severity: A Post Hoc Analysis of the OPTIMUM Study (B1) -  Jul 18, 2022 - Abstract #EAN2022EAN_2422;    
    P3
    Along with prespecified 12- and 24-week CDI analyses, pooled post hoc evaluations of sustained 12-week CDI and EDSS score provide further evidence of clinically meaningful disability improvement with ublituximab in ULTIMATE I and II. In OPTIMUM, patients receiving ponesimod 20 mg were less likely to experience moderate-to-severe relapses than patients receiving teriflunomide 14 mg, and effects were more pronounced in the early illness population (EDSS score ≤3).
  • ||||||||||  teriflunomide / Generic mfg.
    Deep grey matter atrophy in teriflunomide-treated patients with multiple sclerosis (B5) -  Jul 18, 2022 - Abstract #EAN2022EAN_1384;    
    P3
    In contrast to whole brain analyses, dGM atrophy treatment effects were non-significant in this relatively heterogeneous T1w MRI dataset, likely driven by a greater susceptibility of smaller volumes to noise. To improve detection of treatment effects in the dGM, MRI sequences should be standardized and optimized for structural contrasts in these areas.
  • ||||||||||  teriflunomide / Generic mfg.
    Journal:  Hyaluronic acid coated Teriflunomide (A771726) Loaded Lipid Carriers for the Oral Management of Rheumatoid Arthritis. (Pubmed Central) -  Jul 15, 2022   
    In vivo studies demonstrated the superiority of NLCs in increasing TER bioavailability, reducing TNF-α serum levels and improving joint healing that was evidenced in both histopathological and X-ray radiographic examination. This may be attributed to the ability of HA-coated TER-NLCs to target rheumatic joints passively and actively by targeting CD44 receptors that are overexpressed in rheumatic joints.
  • ||||||||||  glatiramer acetate / Generic mfg., teriflunomide / Generic mfg.
    Biomarker, Journal:  IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis. (Pubmed Central) -  Jul 5, 2022   
    The approach demonstrated how quantitative trajectories can help clinicians develop tailored interventions. The IL-2:IL-6 ratio, IL-2, and chitinase 3-like 2 (all in cerebrospinal fluid) might be of value as prognostic biomarkers in early phases of multiple sclerosis.
  • ||||||||||  evobrutinib (M2951) / EMD Serono
    Enrollment open:  EVOLUTION RMS1: Study of Evobrutinib in Participants With RMS (evolutionRMS 1) (clinicaltrials.gov) -  Jul 1, 2022   
    P3,  N=898, Recruiting, 
    Possible alopecia, even if transient, should be considered during patient education when starting DMTs. Active, not recruiting --> Recruiting
  • ||||||||||  evobrutinib (M2951) / EMD Serono
    Enrollment open:  Study of Evobrutinib in Participants With RMS (evolutionRMS 2) (clinicaltrials.gov) -  Jul 1, 2022   
    P3,  N=898, Recruiting, 
    Active, not recruiting --> Recruiting Active, not recruiting --> Recruiting
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Stature: A Prospective Observational Study of the Relationship between Oral Dmt Burden and Adherence in People with MS (Gaylord National Resort & Convention Center - Prince George's Exhibit Hall) -  Jun 30, 2022 - Abstract #CMSC2022CMSC_620;    
    This multi-site prospective longitudinal trial will recruit 323 participants with MS, newly prescribed oral DMTs: cladribine, dimethyl fumarate, fingolimod, teriflunomide, ozanimod, within routine care (n=84 currently recruited)... Information gained will assist prescribing decision-making with consideration for implications of treatment burden on medication adherence, minimising unnecessary healthcare costs and maximizing quality of life for people with MS.